Literature DB >> 9842912

Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization.

M Loetscher1, P Loetscher, N Brass, E Meese, B Moser.   

Abstract

Expression of CXCR3, the receptor for the CXC chemokines IFN-gamma-inducible 10-kDa protein (IP10) and monokine induced by IFN-gamma (Mig), in human T lymphocytes and their responses to IP10 and Mig were analyzed. About 40 % of resting T lymphocytes (and low numbers of B cells and natural killer cells) stained positive for CXCR3 but these cells did not express CXCR3 transcripts and did not respond to these chemokines. However, treatment with IL-2 with or without addition of phytohemagglutinin for 10 or more days resulted in cultures of fully responsive, CXCR3-positive T lymphocytes. Treatment with anti-CD3 antibodies in the presence or absence of soluble anti-CD28 antibodies was inhibitory. Addition of chondroitin sulfate C to CXCR3-expressing murine pre-B cells allowed the determination of high-affinity binding for Mig and IP10 with Kd of 0.9-1.2 nM and 0.2-0.3 nM, respectively, and 1.3 x 10(4) binding sites per cell. The gene for CXCR3 was localized on human chromosome Xq13 which is in clear contrast to all other chemokine receptor genes, suggesting unique function(s) for this receptor and its ligands that may lie beyond their established role in T cell-dependent immunity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9842912     DOI: 10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  109 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

2.  Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.

Authors:  Pia Kivisäkk; Corinna Trebst; Jar-Chi Lee; Barbara H Tucky; Richard A Rudick; James J Campbell; Richard M Ransohoff
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

3.  Innate immunity dictates cytokine polarization relevant to the development of pulmonary fibrosis.

Authors:  Robert M Strieter; Michael P Keane
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

4.  Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis.

Authors:  C Duftner; C Dejaco; W Kullich; A Klauser; C Goldberger; A Falkenbach; M Schirmer
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

Review 5.  The role of CXC chemokines in pulmonary fibrosis.

Authors:  Robert M Strieter; Brigitte N Gomperts; Michael P Keane
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 6.  CXCR3 in carcinoma progression.

Authors:  Bo Ma; Ahmad Khazali; Alan Wells
Journal:  Histol Histopathol       Date:  2015-02-09       Impact factor: 2.303

7.  Interleukin-33 in the human placenta.

Authors:  Vanessa Topping; Roberto Romero; Nandor Gabor Than; Adi L Tarca; Zhonghui Xu; Sun Young Kim; Bing Wang; Lami Yeo; Chong Jai Kim; Sonia S Hassan; Jung-Sun Kim
Journal:  J Matern Fetal Neonatal Med       Date:  2012-11-23

8.  Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay.

Authors:  L A Jopling; G F Watt; S Fisher; H Birch; S Coggon; M I Christie
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

9.  The effects of immunostimulation through dietary manipulation in the rainbow trout; evaluation of mucosal immunity.

Authors:  Carmen Doñate; Joan Carles Balasch; Agnes Callol; Julien Bobe; Lluis Tort; Simon MacKenzie
Journal:  Mar Biotechnol (NY)       Date:  2009-07-16       Impact factor: 3.619

10.  The emerging role of CXCL10 in cancer (Review).

Authors:  Mingli Liu; Shanchun Guo; Jonathan K Stiles
Journal:  Oncol Lett       Date:  2011-05-09       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.